Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis

Children with chronic kidney disease are at high risk for growth retardation and decreased adult height. Growth hormone (GH) treatment is known to stimulate growth in children with short stature suffering from chronic kidney disease. However, the extent to which this the-rapy affects final adult hei...

Full description

Bibliographic Details
Main Author: Doaa Mohammed Youssef
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2012-01-01
Series:Saudi Journal of Kidney Diseases and Transplantation
Online Access:http://www.sjkdt.org/article.asp?issn=1319-2442;year=2012;volume=23;issue=4;spage=755;epage=764;aulast=Youssef
_version_ 1811259262146445312
author Doaa Mohammed Youssef
author_facet Doaa Mohammed Youssef
author_sort Doaa Mohammed Youssef
collection DOAJ
description Children with chronic kidney disease are at high risk for growth retardation and decreased adult height. Growth hormone (GH) treatment is known to stimulate growth in children with short stature suffering from chronic kidney disease. However, the extent to which this the-rapy affects final adult height is not known. This study was performed on 15 patients with end-stage renal disease (ESRD) on regular hemodialysis to detect the effect of using recombinant human growth hormone (rhGH) on growth of patients with ESRD on regular hemodialysis and compa-ring this effect with the growth velocity in the same group without using rhGH in the year before therapy. There were eight females and seven males with mean age 10.6 ± 2.8 (range 5-14 years). For each patient, recombinant GH was given for one year, three-times weekly. The data of these 15 patients was compared with the year before treatment versus data of the same group of patients after six months and after one year of rhGH therapy. Our results showed that, in the year before therapy, height of these patients increased from a mean of 112.1 ± 11.6 cm to 112.7 ± 11.5 cm, which is a non-significant increase statistically (P >0.05) as well as clinically (mean growth velocity 0.6 cm/year), while height of these patients increased from a mean of 112.7 ± 11.5 cm at the start of therapy to 116.8 ± 11 cm after therapy for one year, which, although statically not significant (P >0.05), was of clinical significance as it makes rate of increase, i.e. the mean growth velocity, 4.1 cm/year close to the normal growth velocity, which is 5 cm/year, before puberty. rhGH therapy for patients with ESRD on regular hemodialysis is helpful in height gain and catch-up growth even when given three-times per week instead of five- or six-times per week. We recommend giving rhGH therapy as a routine supplementation to pediatric patients before epiphyseal closure.
first_indexed 2024-04-12T18:27:51Z
format Article
id doaj.art-fe55857051a342f98403d0c412f3cf4e
institution Directory Open Access Journal
issn 1319-2442
language English
last_indexed 2024-04-12T18:27:51Z
publishDate 2012-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Saudi Journal of Kidney Diseases and Transplantation
spelling doaj.art-fe55857051a342f98403d0c412f3cf4e2022-12-22T03:21:10ZengWolters Kluwer Medknow PublicationsSaudi Journal of Kidney Diseases and Transplantation1319-24422012-01-0123475576410.4103/1319-2442.98157Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysisDoaa Mohammed YoussefChildren with chronic kidney disease are at high risk for growth retardation and decreased adult height. Growth hormone (GH) treatment is known to stimulate growth in children with short stature suffering from chronic kidney disease. However, the extent to which this the-rapy affects final adult height is not known. This study was performed on 15 patients with end-stage renal disease (ESRD) on regular hemodialysis to detect the effect of using recombinant human growth hormone (rhGH) on growth of patients with ESRD on regular hemodialysis and compa-ring this effect with the growth velocity in the same group without using rhGH in the year before therapy. There were eight females and seven males with mean age 10.6 ± 2.8 (range 5-14 years). For each patient, recombinant GH was given for one year, three-times weekly. The data of these 15 patients was compared with the year before treatment versus data of the same group of patients after six months and after one year of rhGH therapy. Our results showed that, in the year before therapy, height of these patients increased from a mean of 112.1 ± 11.6 cm to 112.7 ± 11.5 cm, which is a non-significant increase statistically (P >0.05) as well as clinically (mean growth velocity 0.6 cm/year), while height of these patients increased from a mean of 112.7 ± 11.5 cm at the start of therapy to 116.8 ± 11 cm after therapy for one year, which, although statically not significant (P >0.05), was of clinical significance as it makes rate of increase, i.e. the mean growth velocity, 4.1 cm/year close to the normal growth velocity, which is 5 cm/year, before puberty. rhGH therapy for patients with ESRD on regular hemodialysis is helpful in height gain and catch-up growth even when given three-times per week instead of five- or six-times per week. We recommend giving rhGH therapy as a routine supplementation to pediatric patients before epiphyseal closure.http://www.sjkdt.org/article.asp?issn=1319-2442;year=2012;volume=23;issue=4;spage=755;epage=764;aulast=Youssef
spellingShingle Doaa Mohammed Youssef
Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis
Saudi Journal of Kidney Diseases and Transplantation
title Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis
title_full Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis
title_fullStr Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis
title_full_unstemmed Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis
title_short Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis
title_sort results of recombinant growth hormone treatment in children with end stage renal disease on regular hemodialysis
url http://www.sjkdt.org/article.asp?issn=1319-2442;year=2012;volume=23;issue=4;spage=755;epage=764;aulast=Youssef
work_keys_str_mv AT doaamohammedyoussef resultsofrecombinantgrowthhormonetreatmentinchildrenwithendstagerenaldiseaseonregularhemodialysis